Sunesis Pharmaceuticals, Inc.  

(Public, NASDAQ:SNSS)   Watch this stock  
Find more results for SNSS
2.30
+0.10 (4.32%)
Real-time:   11:24AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.18 - 2.34
52 week 1.00 - 8.45
Open 2.22
Vol / Avg. 221,498.00/1.48M
Mkt cap 135.99M
P/E     -
Div/yield     -
EPS -0.84
Shares 61.95M
Beta 2.39
Inst. own 102%
Mar 4, 2015
Q4 2014 Sunesis Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 9, 2014
Sunesis Pharmaceuticals Inc to Discuss Presentation of Phase 3 VALOR Trial Results at ASH Annual Meeting
Nov 18, 2014
Sunesis Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 12, 2014
Sunesis Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 10, 2014
Q3 2014 Sunesis Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1794.50% -434.87%
Operating margin -1558.66% -399.36%
EBITD margin - -399.11%
Return on average assets -116.24% -60.94%
Return on average equity -631.94% -1198.61%
Employees 32 -
CDP Score - -

Address

Suite 400 395 Oyster Point Boulevard
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2663500 (Phone)
+1-650-2663501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The Company focuses on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anti-cancer quinolone derivative (AQD). Vosaroxin has been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company licensed development and commercialization rights to vosaroxin from Dainippon Sumitomo Pharma Co., Ltd. The Company does not have internal manufacturing capabilities for the production of clinical or commercial quantities of vosaroxin.

Officers and directors

Daniel N. Swisher Jr. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Eric H. Bjerkholt Chief Financial Officer, Executive Vice President - Corporate Development and Finance
Age: 54
Bio & Compensation  - Reuters
Adam R. Craig M.D, Ph.D. Executive Vice President - Development, Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Joseph I. DePinto Executive Vice President and Chief Commercial Officer
Age: 46
Bio & Compensation  - Reuters
James W. Young Ph.D. Non-Executive Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. Director
Age: 49
Bio & Compensation  - Reuters
Steve R. Carchedi Independent Director
Age: 52
Bio & Compensation  - Reuters
Matthew K Fust Independent Director
Age: 50
Bio & Compensation  - Reuters
Helen S. Kim Independent Director
Age: 51
Bio & Compensation  - Reuters